BTIG analyst Thomas Shrader reiterated a Buy rating and $9.00 price target on Aldeyra Therapeutics (NASDAQ: ALDX).The analyst comments "Third ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE